A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)

Trial Profile

A Safety and Efficacy Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Coronary Heart Disease (CHD) Patients With a Recent Acute Coronary Syndrome (ACS) Event and Type 2 Diabetes Mellitus (T2D)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2018

At a glance

  • Drugs Aleglitazar (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms AleCARDIO
  • Sponsors Roche
  • Most Recent Events

    • 06 Apr 2018 Results (n=4303) of post hoc analysis comparing the efficacy and safety of aleglitazar with placebo in patients with established or newly diagnosed type 2 diabetes and recent ACS including unstable angina, non-ST segment elevation myocardial infarction, and ST segment elevation myocardial infarction published in the Journal of Clinical Endocrinology and Metabolism
    • 30 Mar 2014 Results published in the JAMA: the Journal of the American Medical Association.
    • 01 Jan 2014 Primary endpoint 'Major-adverse-cardiac-event-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top